DexCom (DXCM) Set to Announce Earnings on Thursday

Thursday, July 22, 2021 | MarketBeat

DexCom (NASDAQ:DXCM) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, July 29th. Analysts expect DexCom to post earnings of $0.44 per share for the quarter. DexCom has set its FY 2021 guidance at - EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 29th. The medical device company reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.02. DexCom had a net margin of 25.36% and a return on equity of 17.86%. The company had revenue of $505.00 million for the quarter, compared to analysts' expectations of $482.67 million. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

NASDAQ DXCM opened at $446.98 on Thursday. DexCom has a 12 month low of $305.63 and a 12 month high of $456.23. The company has a market cap of $43.23 billion, a PE ratio of 87.64 and a beta of 0.79. The business's 50 day moving average price is $400.94. The company has a debt-to-equity ratio of 0.89, a quick ratio of 5.22 and a current ratio of 5.70.

A number of equities research analysts have commented on the stock. Atlantic Securities assumed coverage on shares of DexCom in a research note on Thursday, April 15th. They set an "overweight" rating and a $438.00 target price on the stock. Stephens reaffirmed a "buy" rating and set a $468.00 price objective on shares of DexCom in a report on Thursday, July 1st. Citigroup increased their price objective on shares of DexCom from $480.00 to $488.00 in a report on Friday, April 30th. Barclays started coverage on shares of DexCom in a report on Monday, May 24th. They set an "overweight" rating and a $500.00 price objective for the company. Finally, Canaccord Genuity increased their price objective on shares of DexCom from $445.00 to $455.00 and gave the company a "buy" rating in a report on Friday, April 30th. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of "Buy" and a consensus target price of $466.00.

In other DexCom news, EVP Jacob Steven Leach sold 22,755 shares of DexCom stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $395.00, for a total transaction of $8,988,225.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Sumi Shrishrimal sold 400 shares of DexCom stock in a transaction on Friday, July 16th. The stock was sold at an average price of $450.00, for a total transaction of $180,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,603 shares of company stock valued at $27,159,356. 0.52% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.

See Also: What is the float in trading stocks?

Earnings History for DexCom (NASDAQ:DXCM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in DexCom right now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.